| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/21/2004 | WO2004089346A1 Transdermal administration of (r)-3,3-diphenylpropylamine monoesters |
| 10/21/2004 | WO2004089345A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 10/21/2004 | WO2004089344A1 Process for producing tablet |
| 10/21/2004 | WO2004089343A1 Water soluble tablets |
| 10/21/2004 | WO2004089342A2 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic exipient |
| 10/21/2004 | WO2004089341A1 Organic compounds |
| 10/21/2004 | WO2004089340A1 Pharmaceutical compositions, method, and use of formulation for the treatment and prevention of infections associated with helicobacter pylori in mammals and humans |
| 10/21/2004 | WO2004089339A2 Lipid particles having asymmetric lipid coating and method of preparing same |
| 10/21/2004 | WO2004089338A1 A arbidol clathrate and its preparation process and the use thereof |
| 10/21/2004 | WO2004089337A1 Oral administration form for veterinary use |
| 10/21/2004 | WO2004089336A2 Drug delivery systems comprising an encapsulated active ingredient |
| 10/21/2004 | WO2004089335A2 Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| 10/21/2004 | WO2004089334A2 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| 10/21/2004 | WO2004089333A2 A stable benzimidazole formulation |
| 10/21/2004 | WO2004089329A2 Topical compositions comprising n-acetylamino acids or related n-acetyl compounds |
| 10/21/2004 | WO2004089313A2 Novel olanzapine forms and related methods of treatment |
| 10/21/2004 | WO2004089309A2 Conposition and methods for inhibiting fungal growth and transference |
| 10/21/2004 | WO2004089298A2 5-htp composition |
| 10/21/2004 | WO2004089291A2 Tumor-targeting drug-loaded particles |
| 10/21/2004 | WO2004089290A2 Novel probiotic compositions and methods of using the same |
| 10/21/2004 | WO2004089287A2 Spray dry coacervation systems and methods |
| 10/21/2004 | WO2004089239A2 Topical anthelmintic veterinary formulations |
| 10/21/2004 | WO2004075900A3 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| 10/21/2004 | WO2004075824A3 Pharmaceutical compositions for nasal delivery |
| 10/21/2004 | WO2004075822A3 Pharmaceutical composition for transdermal or transmucosal administration |
| 10/21/2004 | WO2004075817A3 Suspendable pharmaceutical composition |
| 10/21/2004 | WO2004073592A3 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 10/21/2004 | WO2004071402A3 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR |
| 10/21/2004 | WO2004069180A3 Solid dispersion compositions |
| 10/21/2004 | WO2004062642B1 Pharmaceutical safety dosage forms |
| 10/21/2004 | WO2004062640A3 Capsule for receiving an active substance which is administrable by inhalation |
| 10/21/2004 | WO2004050012A3 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 10/21/2004 | WO2004043428A3 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 10/21/2004 | WO2004041250A3 Nanoparticulate fibrate formulations |
| 10/21/2004 | WO2004039315A3 Method for treating wounds to promote healing |
| 10/21/2004 | WO2004037201A3 Topical skin care composition |
| 10/21/2004 | WO2004032626A3 Method for treating an environment that may be or is contaminated with an undesirable bacteria, virus and/or spore |
| 10/21/2004 | WO2004030724A8 Methods and systems for providing orthogonally redundant monitoring in a sedation and analgesia system |
| 10/21/2004 | WO2003099849A3 Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
| 10/21/2004 | WO2003061742A8 Humidity-tight cartridge for a powder inhaler |
| 10/21/2004 | WO2003000014A3 Spherical protein particles and methods of making and using them |
| 10/21/2004 | US20040210280 Plaster-type chip systems for thermodynamic control of topical dermal and transdermal systems |
| 10/21/2004 | US20040210267 Ambulatory medical apparatus and method using a robust communication protocol |
| 10/21/2004 | US20040210184 Effect of electric field and ultrasound for transdermal drug delivery |
| 10/21/2004 | US20040209963 dispersing in an aqueous phase a solution of an active substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing mixture and separating dispersion from gaseous solvent; dispersed particles are in micro or nano size range |
| 10/21/2004 | US20040209961 Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
| 10/21/2004 | US20040209955 preservative-free aqueous solution of sodium gamma-hydroxybutyrate, and a pH adjusting agent; pH of 6-7.5; chemically stable and resistant to microbial growth |
| 10/21/2004 | US20040209944 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection |
| 10/21/2004 | US20040209919 2-[(2-pyridyl)methylsulfinyl]benzimidazole derivative stabilized with an inorganic salt of magnesium, calcium, potassium, or sodium; gastric acid secretion inhibitors |
| 10/21/2004 | US20040209911 Mixture containing rapamycin; absorption efficiency |
| 10/21/2004 | US20040209909 in a carrier effective to permit sustained release at a therapeutically effective rate over an administration period of at least 8 hours |
| 10/21/2004 | US20040209907 administering anagrelide, anagrelide in base form, or a salt of anagrelide so that first pass liver metabolism is avoided. |
| 10/21/2004 | US20040209906 Composition comprising ketanserin AND AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209855 use of estradiol metabolites such as 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol; few side effects |
| 10/21/2004 | US20040209852 Formulations and methods for treating rhinosinusitis |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209815 Compositions providing for increased IGF-I solubility |
| 10/21/2004 | US20040209811 comprising water-soluble formula and/or enteric-coated formula (C-phycocyanin, allophycocyanin, spirulina growth factor) |
| 10/21/2004 | US20040209807 Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| 10/21/2004 | US20040209366 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 10/21/2004 | US20040209333 administering subtilisins obtained from grampositive bacterial residues that vitamin k2 has been removed using chitosan |
| 10/21/2004 | US20040208985 An implant, a stent, having coatings of polyampholyte matrix swollen in a drug-containing solution from which the drug is imbibed; time-release agents; acrylic monomers including a zwitterionic monomer, e.g., 2-methacryloyloxyethyl-2'- trimethylammoniumethylphosphate inner salt; side effect reduction |
| 10/21/2004 | US20040208946 Tablet press machine |
| 10/21/2004 | US20040208938 for needles comprising time release microparticles containing risperidones, glycolic acid-lactic acid copolymer binders, and high viscosity aqueous fluids (containing sodium carboxymethyl cellulose as modifier) |
| 10/21/2004 | US20040208937 Triggered release from proteinoid microspheres |
| 10/21/2004 | US20040208936 Novel compositions |
| 10/21/2004 | US20040208935 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 10/21/2004 | US20040208934 Dispersions or complexes of calcium phosphate in polymers such as polyethylene glycol or dextran sulfate; solid matrix due to hydration; contains active agent; matrix polymer and/or complexing agent slows release of active agent from solid matrix |
| 10/21/2004 | US20040208932 moisture stable pharmaceutical preparation in form of solid oral dose comprising active core of granulated pharmaceutically active ingredient and moisture barrier coating enveloping individual granules of active core |
| 10/21/2004 | US20040208931 Fast dissolving films for oral administration of drugs |
| 10/21/2004 | US20040208930 produced by coating core particles with layer containing water-soluble drug and forming film layer containing water-insoluble polymer and plasticizer on particles and forming water-soluble filler layer between water-soluble drug-containing layer and film layer |
| 10/21/2004 | US20040208929 specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition |
| 10/21/2004 | US20040208928 dispersing powdered ethylcellulose with diameter of 0.1 mu m to 300 mu m in aqueous dispersion to provide enteric encapsulant; mixing biologically active ingredient and enteric encapsulant; spray-drying |
| 10/21/2004 | US20040208927 Process for preparing non-hygroscopic sodium valproate composition |
| 10/21/2004 | US20040208926 comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments, in particular digestive fluids of the gastrointestinal tract |
| 10/21/2004 | US20040208925 alendronate particles coated with polymer insoluble at pH 6-7.5, and alginic acid or sodium alginate or admixtures there of, where alendronate dissolves in 900 ml 0.1 N HCl at the rate of not less than 85% within 30 minutes at pH 1-4; decreases esophageal and gastric side effects of alendronate |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208922 Method for loading lipid like vesicles with drugs or other chemicals |
| 10/21/2004 | US20040208921 Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| 10/21/2004 | US20040208920 injectable liposomal composition for delivery of large amounts of water-soluble substance comprises a plurality of liposomal vesicles having a high weight ratio of lipid to encapsulated water-soluble substance which is distributed over the liposomal vesicles; high efficiency of encapsulation |
| 10/21/2004 | US20040208918 administering constituent which effects a local increase in temperature and/or an increase in blood flow of the skin in addition to the transdermally applied active substance |
| 10/21/2004 | US20040208917 using clonidine-containing adhesive layer based on styrene block polymers, styrene block copolymers; treatment of hypertonia, migraines, anxieties, hyperkinetic behavioral disorders, alcohol or drug-related withdrawal systems, and menopausal symptoms |
| 10/21/2004 | US20040208916 Patch for the transdermal administration of beneficial substances |
| 10/21/2004 | US20040208915 Transdermal administration device for animals |
| 10/21/2004 | US20040208910 Sustained release device and method for ocular delivery of adrenergic agents |
| 10/21/2004 | US20040208909 comprising a drug core, a unitary cup, and a permeable plug; for delivering multiple agents directly to the interior portions of the body of a mammalian organism, such as to eye |
| 10/21/2004 | US20040208895 administering HETEROLOGOUS GENE PRODUCTS IN HOST CELL SYSTEMS AND/OR TO RESCUE NEGATIVE STRAND RNA RECOMBINANT VIRUSES |
| 10/21/2004 | US20040208860 Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 10/21/2004 | US20040208854 Methods and compositions for controlled release of bioactive compounds |
| 10/21/2004 | US20040208853 Method and device for sanitation using bacteriophages |
| 10/21/2004 | US20040208851 Immunization by inoculation of DNA transcription unit |
| 10/21/2004 | US20040208833 Novel fluticasone formulations |
| 10/21/2004 | US20040208831 Nasal pharmaceutical formulations and methods of using the same |
| 10/21/2004 | US20040208830 Fluticasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; rhinitis treatment |
| 10/21/2004 | US20040208829 Methods and compositions for treating erectile dysfunction |
| 10/21/2004 | US20040206703 Circulating liquid in conduit; injecting ions into fluid flow; controlling concentration profile; salt formation |
| 10/21/2004 | US20040206157 Determination of gas-free densities and relative amounts of gases in liquids in manufacturing processes |
| 10/21/2004 | US20040205910 supplying hair dyes, melanin, proteins, nucleic acids; encapsulated in liposomes |
| 10/21/2004 | DE10316280A1 Pharmazeutisches Schaumaerosol für Dexpanthenol A pharmaceutical aerosol foam for panthenol |